Generation Bio Co. Statistics
Total Valuation
GBIO has a market cap or net worth of $200.10 million. The enterprise value is $27.84 million.
| Market Cap | 200.10M |
| Enterprise Value | 27.84M |
Important Dates
The next estimated earnings date is Wednesday, May 8, 2024, after market close.
| Earnings Date | May 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
GBIO has 66.48 million shares outstanding. The number of shares has increased by 10.96% in one year.
| Shares Outstanding | 66.48M |
| Shares Change (YoY) | +10.96% |
| Shares Change (QoQ) | +0.26% |
| Owned by Insiders (%) | 14.49% |
| Owned by Institutions (%) | 79.95% |
| Float | 48.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 33.89 |
| Forward PS | 25.55 |
| PB Ratio | 0.99 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.71 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.83, with a Debt / Equity ratio of 0.48.
| Current Ratio | 6.83 |
| Quick Ratio | 6.87 |
| Debt / Equity | 0.48 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -52.30% and return on invested capital (ROIC) is -46.03%.
| Return on Equity (ROE) | -52.30% |
| Return on Assets (ROA) | -31.80% |
| Return on Capital (ROIC) | -46.03% |
| Revenue Per Employee | $33,931 |
| Profits Per Employee | -$727,655 |
| Employee Count | 174 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.71% in the last 52 weeks. The beta is 2.79, so GBIO's price volatility has been higher than the market average.
| Beta (1Y) | 2.79 |
| 52-Week Price Change | -34.71% |
| 50-Day Moving Average | 3.09 |
| 200-Day Moving Average | 2.93 |
| Relative Strength Index (RSI) | 44.62 |
| Average Volume (30 Days) | 241,146 |
Short Selling Information
The latest short interest is 1.58 million, so 2.38% of the outstanding shares have been sold short.
| Short Interest | 1.58M |
| Short Previous Month | 1.14M |
| Short % of Shares Out | 2.38% |
| Short % of Float | 3.27% |
| Short Ratio (days to cover) | 6.33 |
Income Statement
In the last 12 months, GBIO had revenue of $5.90 million and -$126.61 million in losses. Loss per share was -$1.96.
| Revenue | 5.90M |
| Gross Profit | 5.90M |
| Operating Income | -138.56M |
| Pretax Income | -126.61M |
| Net Income | -126.61M |
| EBITDA | -121.35M |
| EBIT | -126.61M |
| Loss Per Share | -$1.96 |
Balance Sheet
The company has $270.16 million in cash and $97.89 million in debt, giving a net cash position of $172.26 million or $2.59 per share.
| Cash & Cash Equivalents | 270.16M |
| Total Debt | 97.89M |
| Net Cash | 172.26M |
| Net Cash Per Share | $2.59 |
| Equity / Book Value | 203.13M |
| Book Value Per Share | 3.06 |
| Working Capital | 232.70M |
Cash Flow
In the last 12 months, operating cash flow was -$52.75 million and capital expenditures -$7.40 million, giving a free cash flow of -$60.14 million.
| Operating Cash Flow | -52.75M |
| Capital Expenditures | -7.40M |
| Free Cash Flow | -60.14M |
| FCF Per Share | -$0.93 |
Margins
Gross margin is 100.00%, with operating and profit margins of -2,346.93% and -2,144.51%.
| Gross Margin | 100.00% |
| Operating Margin | -2,346.93% |
| Pretax Margin | -2,144.51% |
| Profit Margin | -2,144.51% |
| EBITDA Margin | -2,055.37% |
| EBIT Margin | -2,144.51% |
| FCF Margin | -1,018.67% |
Dividends & Yields
GBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.96% |
| Shareholder Yield | -10.96% |
| Earnings Yield | -63.28% |
| FCF Yield | -30.06% |
Analyst Forecast
The average price target for GBIO is $8.00, which is 165.78% higher than the current price. The consensus rating is "Buy".
| Price Target | $8.00 |
| Price Target Difference | 165.78% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | -24.71% |
| EPS Growth Forecast (5Y) | -4.71% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GBIO has an Altman Z-Score of -1.79 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.79 |
| Piotroski F-Score | 1 |